Pfizer Inc (PFE) News 31.88 $PFE
From Marijuana to Snake Venom: 9 Drugs Derived from Unlikely Sources
Sean Williams, The Motley Fool - Motley Fool - 16 mins ago
Every sector relies on innovation to grow to some extent, but it's possibly the most vital component to success in the biotech sector. Biopharmaceutical companies don't have the luxury of simply sitting on their laurels and living off of the...
Why Big U.S. Companies Park Billions Overseas
Dan Caplinger, The Motley Fool - Motley Fool - 2 hrs 8 mins ago
As you scurry to pay your taxes, hundreds of U.S. companies are saving billions of dollars by parking their money outside the U.S. and avoiding taxation. With a recent Bloomberg study showing that big companies added more than $200 billion to their...
Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium(R) 24HR
Business Wire - Fri Mar 28, 5:26PM CDT
Today the U.S. Food and Drug Administration (FDA) approved over-the-counter Nexium(R) 24HR (esomeprazole 20mg) marking a key step towards providing those who suffer from frequent heartburn broader access to a brand doctors and patients have trusted for years.
Most active New York Stock Exchange-traded stocks
AP - Fri Mar 28, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Fri Mar 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Encouraging Data on Pfizer Cholesterol Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:37PM CDT
Pfizer announced encouraging results from a phase IIb study on bococizumab.
Does Arena Pharmaceuticals Have An Anti-Smoking Opportunity?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 28, 1:30PM CDT
Drugs that go on to garner the coveted blockbuster status, or $1 billion in annual sales, are often able to do so by being used for multiple indications. This can be achieved through either a formal label expansion process involving clinical trials...
CONSOL Energy Is the Champion This March
Taylor Muckerman and Alison Southwick, The Motley Fool - Motley Fool - Fri Mar 28, 12:47PM CDT
In the final round match-up of The Motley Fool Better-Buy Tournament, CONSOL Energy bested Universal Display by a healthy margin it its battle to determine which stock is the better buy now. The 64-company tournament pitted two Motley Fool...
Midday Glance: Pharmaceuticals companies
AP - Fri Mar 28, 12:32PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
This Rapidly Evolving New Cholesterol Treatment Pathway Demands Your Attention
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 28, 11:08AM CDT
According to the National Institutes of Health, there are 163,000 clinical studies currently under way throughout 185 countries. This is why it can sometimes be difficult to get the attention of investors when a revolutionary new treatment pathway...
Technical Summary on Active Stocks -- Research on Cisco Systems, Pfizer, Vale, and Advanced Micro Devices
PR Newswire - Fri Mar 28, 10:31AM CDT
The trading session on Thursday, March 27, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,264.23, down 0.03% and the NASDAQ Composite closed at 4,151.23, down 0.54%. The S&P 500 finished the session 0.19% lower at 1,849.04. The losses were broad based as seven out of ten sectors ended the session in negative. During the session, Information Technology, Financials, and Consumer Discretionary sectors exerted a drag, while some positive momentum was observed in the Telecommunication Services, Energy, and Utilities sectors. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Cisco Systems Inc. (NASDAQ: CSCO), Pfizer Inc. (NYSE: PFE), Vale S.A. (NYSE: VALE) and Advanced Micro Devices Inc. (NYSE: AMD). Free technical research on CSCO, PFE, VALE and AMD can be downloaded upon signing up at:
Baxter Hits 52-Week High on Planned Business Split-Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 9:24AM CDT
BAX expects to complete splitting up the business in mid-2015
Early Glance: Pharmaceuticals companies
AP - Fri Mar 28, 9:23AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
Pfizer (PFE) Approaches New Upside Target of $32.61
Comtex SmarTrend(R) - Fri Mar 28, 9:03AM CDT
Pfizer (NYSE
FE) has opened bullishly above the pivot of $32.13 today and has reached the first level of resistance at $32.35. Analysts will be watching for a cross of the next upside pivot targets of $32.61 and $33.09.
Dow 30 Stock Roundup: Pfizer Gains, Crimea, Biotech Stocks Drag Markets - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Mar 28, 8:55AM CDT
The Dow has had a poor run this week, primarily due to a selloff in biotech stocks and the resurgence of concerns over Crimea.
Positive Opinions, Presentation Schedules of Investigational Data, Clinical Study Results, and Stock Price Movements - Analyst Notes on Johnson & Johnson, Merck, Pfizer, Amgen, and Allergan
PR Newswire - Fri Mar 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE), Amgen Inc. (NASDAQ: AMGN), and Allergan Inc. (NYSE: AGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Business Highlights
By The Associated Press - AP - Thu Mar 27, 4:29PM CDT
___
Positive Data on Pfizer's Genotropin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 3:31PM CDT
Pfizer announced encouraging data from a phase IIIb study evaluating Genotropin.
From Marijuana to Snake Venom: 9 Drugs Derived from Unlikely Sources
Sean Williams, The Motley Fool - Motley Fool - 16 mins ago
Every sector relies on innovation to grow to some extent, but it's possibly the most vital component to success in the biotech sector. Biopharmaceutical companies don't have the luxury of simply sitting on their laurels and living off of the...
Why Big U.S. Companies Park Billions Overseas
Dan Caplinger, The Motley Fool - Motley Fool - 2 hrs 8 mins ago
As you scurry to pay your taxes, hundreds of U.S. companies are saving billions of dollars by parking their money outside the U.S. and avoiding taxation. With a recent Bloomberg study showing that big companies added more than $200 billion to their...
Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium(R) 24HR
Business Wire - Fri Mar 28, 5:26PM CDT
Today the U.S. Food and Drug Administration (FDA) approved over-the-counter Nexium(R) 24HR (esomeprazole 20mg) marking a key step towards providing those who suffer from frequent heartburn broader access to a brand doctors and patients have trusted for years.
Most active New York Stock Exchange-traded stocks
AP - Fri Mar 28, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Fri Mar 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Encouraging Data on Pfizer Cholesterol Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:37PM CDT
Pfizer announced encouraging results from a phase IIb study on bococizumab.
Does Arena Pharmaceuticals Have An Anti-Smoking Opportunity?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 28, 1:30PM CDT
Drugs that go on to garner the coveted blockbuster status, or $1 billion in annual sales, are often able to do so by being used for multiple indications. This can be achieved through either a formal label expansion process involving clinical trials...
CONSOL Energy Is the Champion This March
Taylor Muckerman and Alison Southwick, The Motley Fool - Motley Fool - Fri Mar 28, 12:47PM CDT
In the final round match-up of The Motley Fool Better-Buy Tournament, CONSOL Energy bested Universal Display by a healthy margin it its battle to determine which stock is the better buy now. The 64-company tournament pitted two Motley Fool...
Midday Glance: Pharmaceuticals companies
AP - Fri Mar 28, 12:32PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
This Rapidly Evolving New Cholesterol Treatment Pathway Demands Your Attention
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 28, 11:08AM CDT
According to the National Institutes of Health, there are 163,000 clinical studies currently under way throughout 185 countries. This is why it can sometimes be difficult to get the attention of investors when a revolutionary new treatment pathway...
Technical Summary on Active Stocks -- Research on Cisco Systems, Pfizer, Vale, and Advanced Micro Devices
PR Newswire - Fri Mar 28, 10:31AM CDT
The trading session on Thursday, March 27, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,264.23, down 0.03% and the NASDAQ Composite closed at 4,151.23, down 0.54%. The S&P 500 finished the session 0.19% lower at 1,849.04. The losses were broad based as seven out of ten sectors ended the session in negative. During the session, Information Technology, Financials, and Consumer Discretionary sectors exerted a drag, while some positive momentum was observed in the Telecommunication Services, Energy, and Utilities sectors. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Cisco Systems Inc. (NASDAQ: CSCO), Pfizer Inc. (NYSE: PFE), Vale S.A. (NYSE: VALE) and Advanced Micro Devices Inc. (NYSE: AMD). Free technical research on CSCO, PFE, VALE and AMD can be downloaded upon signing up at:
Baxter Hits 52-Week High on Planned Business Split-Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 9:24AM CDT
BAX expects to complete splitting up the business in mid-2015
Early Glance: Pharmaceuticals companies
AP - Fri Mar 28, 9:23AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
Pfizer (PFE) Approaches New Upside Target of $32.61
Comtex SmarTrend(R) - Fri Mar 28, 9:03AM CDT
Pfizer (NYSE
FE) has opened bullishly above the pivot of $32.13 today and has reached the first level of resistance at $32.35. Analysts will be watching for a cross of the next upside pivot targets of $32.61 and $33.09. Dow 30 Stock Roundup: Pfizer Gains, Crimea, Biotech Stocks Drag Markets - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Mar 28, 8:55AM CDT
The Dow has had a poor run this week, primarily due to a selloff in biotech stocks and the resurgence of concerns over Crimea.
Positive Opinions, Presentation Schedules of Investigational Data, Clinical Study Results, and Stock Price Movements - Analyst Notes on Johnson & Johnson, Merck, Pfizer, Amgen, and Allergan
PR Newswire - Fri Mar 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE), Amgen Inc. (NASDAQ: AMGN), and Allergan Inc. (NYSE: AGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Business Highlights
By The Associated Press - AP - Thu Mar 27, 4:29PM CDT
___
Positive Data on Pfizer's Genotropin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 3:31PM CDT
Pfizer announced encouraging data from a phase IIIb study evaluating Genotropin.
